Skip to main content
颖泰生物 logo

颖泰生物 — Investor Relations & Filings

Ticker · 920819 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 419 across all filing types
Latest filing 2023-12-10 Capital/Financing Update
Country CN China
Listing Beijing Stock Exchange 920819

About 颖泰生物

https://www.nutrichem.cn/

Nutrichem Company Limited focuses on the research, development, production, and distribution of agrochemical active ingredients and formulations. The product portfolio includes a diverse array of herbicides, fungicides, and insecticides tailored for global agricultural applications. The company provides comprehensive contract development and manufacturing organization (CDMO) services, supporting international partners through the entire product lifecycle from synthesis to commercial-scale production. With a strong emphasis on research and development, Nutrichem utilizes advanced chemical synthesis technologies and process optimization to ensure high-quality output and operational efficiency. Its integrated supply chain and large-scale manufacturing infrastructure enable the delivery of customized crop protection solutions to meet the evolving needs of the global agricultural sector.

Recent filings

Filing Released Lang Actions
关于2024年度提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the company's plan to provide guarantees for loans in the 2024 fiscal year. It includes specifics about the guarantee amounts, the companies involved, credit status, board approval, and legal compliance. It is not a financial report like an annual or interim report, nor is it a transcript, audit report, or earnings release. It is a formal announcement about financing-related guarantees and credit support, which fits best under Capital/Financing Update (CAP). The document length is over 10,000 characters and contains substantive details about financing guarantees, not just a brief notice or regulatory filing. Therefore, the classification is CAP with high confidence.
2023-12-10 Chinese
关于部分募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Beijing Yingtai Jiahe Biotechnology Co., Ltd. regarding the delay of certain projects funded by raised capital. It details the background of the fundraising, the investment projects, reasons for the delay, and the impact on the company. It includes references to regulatory approvals, board and supervisory committee meetings, and opinions from the sponsor institution. The document is relatively short (3166 characters) and focuses on the update about the delay of capital investment projects rather than presenting financial statements or comprehensive financial data. It is not a full financial report, audit report, or earnings release. It is an update on the use and progress of raised funds, which fits the category of Capital/Financing Update (CAP).
2023-12-10 Chinese
第四届监事会第三次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolution passed at the third meeting of the fourth Supervisory Board of Beijing Yingtai Jiahe Biotechnology Co., Ltd. It details the meeting's convening, attendance, and the approval of a proposal regarding the delay of some fundraising projects. The document references another announcement for detailed content but itself is a meeting resolution announcement. It does not contain financial statements, audit information, or detailed management discussion. It is not a full report but a formal board/management information disclosure about a supervisory board meeting resolution. Therefore, it fits best under Board/Management Information (MANG). The document length is short and focused on board meeting decisions, not a report or announcement of voting results or other categories.
2023-12-10 Chinese
西南证券股份有限公司关于北京颖泰嘉和生物科技股份有限公司2024年度提供担保的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from Southwest Securities Co., Ltd. regarding the 2024 guarantee provision by Beijing Yingtai Jiahe Biotechnology Co., Ltd. It details the guarantee amounts, terms, and approval process related to financing guarantees for the year 2024. The document includes tables of guarantee limits, approval by the board, and compliance with regulatory rules. It is not a full financial report, audit report, or earnings release, but rather a regulatory compliance and verification statement related to guarantees. The document length is 2668 characters, which is relatively short and focused on a specific regulatory compliance matter. This fits best under Regulatory Filings (RNS), as it is a compliance-related announcement and verification opinion rather than a full report or financial statement.
2023-12-10 Chinese
西南证券股份有限公司关于北京颖泰嘉和生物科技股份有限公司预计2024年日常关联交易的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed review and opinion from Southwest Securities Co., Ltd. regarding the expected related party transactions of Beijing Yingtai Jiahe Biotechnology Co., Ltd. for the year 2024. It includes descriptions of the types and amounts of related party transactions, the parties involved, pricing basis, fairness, approval procedures, and the sponsor's verification opinion. The document is a formal verification and opinion letter related to regulatory compliance and disclosure of related party transactions, not a financial report or earnings release. It does not contain financial statements or quarterly/yearly financial results. It is a regulatory compliance and disclosure document related to related party transactions, which fits best under Regulatory Filings (RNS) as it does not match other specific categories like Annual Report, Interim Report, or Audit Report. The document length is 6556 characters, which is substantive and not a mere announcement or certification letter, but the content is clearly a regulatory filing about related party transactions and sponsor opinion.
2023-12-10 Chinese
关于2024年度开展远期结售汇等外汇衍生产品业务的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from the company's board regarding the approval to conduct foreign exchange derivative product business for the year 2024. It details the business purpose, types of products, expected business scale, risk analysis, and risk control measures. The document is a formal announcement of a board decision rather than a financial report or detailed management discussion. It does not contain financial statements, earnings data, or regulatory certifications. It is not a report publication announcement since it contains substantive content about the business plan and risk management. The document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about business activities and board resolutions that do not fit other specific categories.
2023-12-10 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.